SPINK1 and colorectal carcinoma: In order to study the effects of various MAPK pathway inhibitors on the SPINK1 levels, CRC cell lines were treated with the following compounds: gefitinib, GW5074, LY294002, PD98059, salisarib, SCH772984, trametinib, vemurafenib, and zoledronic acid.